Dr. Arun Chandavarkar is the Chief Executive Officer (CEO) & Joint Managing Director at Biocon Limited, one of Asia’s leading bio-pharmaceuticals companies. Biocon’s focus on innovation and affordable biopharmaceuticals targeting chronic disease like diabetes, oncology and autoimmune conditions would enhance access for these patients worldwide.  Dr. Chandavarkar has played a critical role in the evolution of Biocon during the past 25 years of his association with the Company. He graduated in Chemical Engineering from the Indian Institute of Technology, Mumbai and holds a Ph.D. in Biochemical Engineering from MIT, Cambridge, USA. He joined Biocon as General Manager - Operations in 1990, took on the role of President - Operations & Technology and subsequently became the Chief Operating Officer in 2006. He is currently Chairperson of the National CII Committee on Biotechnology for the year 2016-17.

Under his leadership, Biocon has developed deep expertise in diverse technology platforms spanning microbial fermentation, cell culture, chemical synthesis and purification to develop a wide portfolio of products from specialty enzymes to complex active pharmaceutical ingredients to recombinant therapeutic proteins. As CEO and Joint Managing Director of Biocon, Dr. Chandavarkar is now leading the company into its next phase of evolution, where it is rapidly gaining recognition as an innovation led global biopharmaceutical company.